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Abstract
Purpose Antidepressants, specifically selective serotonin
reuptake-inhibiting antidepressants (SSRIs), decrease platelet
activation and aggregation in in vitro experiments and could
therefore decrease the risk of myocardial infarction (MI).
However, prior studies addressing this hypothesis showed
contradictory results. Our purpose was to investigate the asso-
ciation between the use of any antidepressant drug and inci-
dent MI among middle-aged and older adults.
Methods We embedded a case-control study in the prospec-
tive Rotterdam Study (1991–2011). Controls were matched to
MI cases based on sex and age at the same calendar date, and
confounding factors were taken into account as time-varying
covariates. The relative risk of MI during current and past use
of an antidepressant was analyzed with conditional logistic
regression with never use of antidepressant drugs as the
reference category.
Results A total of 744 out of a cohort of 9499 study partici-
pants developed MI during follow-up. After statistical adjust-
ment for traditional cardiovascular risk factors and depression,
current use of any antidepressant was associated with a lower
risk of MI (odds ratio (OR), 0.71; 95 % confidence interval
(CI), 0.51–0.98) compared with never use of any antidepres-
sant. SSRI use showed the lowest relative risk (OR, 0.65;
95 % CI, 0.41–1.02), albeit marginally not statistically signif-
icant. Past use of any of the antidepressant classes was not
associated with a lower risk of MI.
Conclusions Current use of antidepressants was associated
with a lower risk of MI. Of the different classes, the use of
SSRIs showed the lowest risk of MI, and therefore confirming
the research hypothesis.
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Introduction
Findings from in vitro experiments have led to the hypothesis
that the use of antidepressant drugs, and specifically use of
selective serotonin reuptake inhibitors (SSRIs), might de-
crease the risk of myocardial infarction (MI). The inhibition
of the serotonin reuptake transporter on blood platelets by
SSRIs decreases platelet activation and aggregation in
in vitro experiments [1, 2]. Similarly, antidepressants other
than SSRIs might decrease platelet activation and aggregation
by antagonizing the serotonin receptor and/or inhibiting also
serotonin reuptake, although with lower affinity than SSRIs
[3, 4].
Studies addressing the hypothesis of a lower risk of MI
during use of SSRIs showed inconsistent results. Some studies
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reported a lower risk of MI in users of SSRIs [5, 6], while
others showed no decreased risk [7–10] or an increased risk
[11, 12]. Depression is associatedwith an increased risk ofMI,
and it may therefore complicate the interpretation of the study
results [13–18]. Only one randomized clinical trial comparing
cardiovascular event rates in antidepressants and placebo has
been published [9]. In that study, a 30 % lower, but nonsig-
nificant, risk of MI was observed in users of sertraline com-
pared with users of placebo treatment. Tricyclic antidepres-
sants (TCAs), which decrease platelet activation and aggrega-
tion to some extent [3, 4], were associated with higher risk of
MI [10, 11].
Thus, despite evidence of decreased blood platelet aggrega-
tion in in vitro experiments with antidepressants, more studies
are required to shed light on this association. When we have
more insights on the antiplatelet effects of antidepressants in the
general population, clinical practice might benefit by adjusting
treatment strategies. Studies using time-varying exposure of
antidepressants as well as controlling for depression might pro-
vide further insights. Within this study, we aimed to investigate
the association between use of any antidepressant and risk of
MI in the general middle-aged and older population.
Methods
Study setting
The current studywas conducted in the prospective population-
based Rotterdam Study, designed to investigate risk factors for
age-related diseases. From 1990 to 1993, all inhabitants aged
55 years and older from the Ommoord district located in
Rotterdam, The Netherlands, were invited to participate in
RS-I. In total, 7983 individuals agreed to participate (response
rate 78 %). In 2000, all inhabitants of Ommoord aged 55 years
and older were asked to participate in an extension of the orig-
inal cohort when they were not previously invited. In total,
3011 individuals agreed to participate (response rate 67 %).
Follow-up examinations were conducted every 3–4 years after
baseline. Amore detailed description of the Rotterdam Study is
published elsewhere [19, 20]. The Rotterdam Study has been
approved by the medical ethics committee according to the
BWet Bevolkingsonderzoek: ERGO^ (Population Study Act
Rotterdam Study), executed by the Ministry of Health, Welfare
and Sports of The Netherlands, and written informed consent
was obtained from all study participants.
Study population and design
For the present study, we included all participants from the
Rotterdam Study cohorts free of MI at baseline. Within the
prospective cohort, cases of MI were matched to all eligible
participants in the cohort without MI with the same sex, and a
similar age (±1 year) at the event date. For every matched set,
the exposure status to antidepressants and covariates in each
case and its corresponding controls was assessed on the event
date as described below. Cases were censored at the event
date, whereas controls were allowed to develop MI at a later
date during the course of follow-up.
Antidepressant drug exposure
More than 95% of the participants have their drug prescriptions
filled at one of the seven regional pharmacies. From 1 January
1991 onwards, complete dispensing data is available on a day-
to-day basis, which includes the Anatomical Therapeutical
Chemical (ATC) code of the drug [21], the dispensing date,
the total number of drug units per prescription, the prescribed
daily number of units, and the product name of the drug.
A dispensing episode was calculated by dividing the total
number of filled tablets/capsules by the daily prescribed num-
ber. Antidepressant use (based on ATC code, N06A) was ad-
ditionally subdivided into TCAs (ATC code = N06AA),
SSRIs (ATC code = N06AB), and other antidepressants
(ATC code = N06AX). Participants were defined as current
user when the event date fell within a dispensing episode.
Participants were considered past users, if they previously
filled an antidepressant, TCA or SSRI dispensing during fol-
low-up, but were not current users. The period during which
participants were not using antidepressants on the index date
and had not used them in the past was defined as never use.
Validation of the study outcomes
Both cohorts were continuously monitored for the occurrence
of major morbidity and mortality through linkage with the
records from the general practitioner. MI (fatal and nonfatal)
was adjudicated based on a combination of symptoms, ECG
measurements, and enzymemarkers indicative of the presence
ofMI, as described inmore detail elsewhere [22]. All potential
MI cases were independently adjudicated by two research
physicians. Amedical specialist, whose judgment was consid-
ered final, reviewed all potential cases.
All-cause mortality was based on information from the
Central Register of Population of the municipality of
Rotterdam and collaborating general practitioners.
Covariates
The following covariates were considered as potential con-
founders: bodymass index (BMI), systolic and diastolic blood
pressure, highest reached level of education, high-density
lipoprotein (HDL) and total cholesterol levels, treated diabetes
mellitus, smoking status, history of heart failure, history of
venous thromboembolism, presence of depression and/or
anxiety, use of blood-pressure-lowering drugs, beta-blockers,
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cholesterol-lowering agents, anxiolytics, hypnotics, and
antipsychotics. A detailed description of how these variables
were collected is given in an Online supplementary material.
Statistical analyses
The association between current antidepressant use and risk of
MI was studied using conditional logistic regression analyses
with never users of antidepressants as the reference population
(analysis 1). This analysis was conducted using unimputed
(analysis 1A) data and data after multiple imputations (5 times;
6.5 % maximally missing; analysis 1B). In addition, we also
compared the risk of MI between current and past use of anti-
depressants (analysis 2). We present results for all models un-
adjusted (model 1) and multivariably adjusted (models 2 and
3).Model 2 was adjusted for all covariates that were considered
potential confounding factors. Model 3 is additionally adjusted
for covariates that were considered potential intermediate fac-
tors, based on previous research [23–26]. The potential inter-
mediate factors were BMI, total cholesterol, HDL cholesterol,
use of statins, and diabetes mellitus. The analyses conducted
using model 2 were repeated per antidepressant drug class
(TCA and SSRI). Because use of other antidepressants was
low, we did not evaluate those separately. We additionally con-
ducted analyses in which the period of past antidepressant use
started 7, 14, and 30 days after the last day of a filled treatment
period to eliminate potential withdrawal effects.
A number of additional analyses were conducted. First, we
assessed the association with the number of concomitantly
prescribed cardiovascular drugs (ATC codes: BB01A,^ BC02,
^ BC03,^ BC07,^ BC08,^ BC09,^ BC10AA^) and studied the
percentage of antidepressant use within these strata. In addition,
we restricted our population to cases and controls that used at
most one of these cardiovascular drugs, and thus excluding
those with the highest cardiovascular risk, and repeated the
analyses of the risk of MI. And second, we studied the associ-
ation between current use of antidepressants and mortality
(compared with nonuse and past use of antidepressants). The
dataset for the analysis on all-cause mortality was similarly
constructed as for the analysis on MI, as is described above.
Results from these analyses provide arguments whether results
in the overall analysis were subjected by residual confounding
and/or confounding by indication.
We used IBM SPSS Statistics (version 21.0, IBM Corp.,
Somers, NY, USA) for all analyses.
Results
Characteristics of the study population
A total of 744 MI cases (during 101,664 person years) were
successfully matched to controls from the total cohort of 9499
participants (Table 1). At baseline, participants who developed
anMI during follow-up were, on average, 69.7 years(standard
deviation (SD), 8.1), and 44.8 % were women. The total co-
hort had a mean age of 69.4 years (SD, 8.7) at baseline, and
60.9 % were women.
Antidepressant use and risk of MI
Of the 744 MI cases, 19 were current users and 93 were past
users of antidepressants (Table 2). Compared with never use
of antidepressants, current use of any antidepressant was as-
sociated with a lower risk of MI (analysis 1B, model 1: odds
ratio (OR), 0.71; 95 % confidence interval (CI), 0.51–0.98)
after adjustment for confounding factors (model 2). These
results remained similar when adjusted for potential interme-
diate factors (model 3). We observed no association between
past use of antidepressants and the risk of MI after adjustment
for confounding factors (analysis 1B, model 2; OR, 1.17;
95 % CI, 0.95–1.45).
With past use of antidepressants as reference, current anti-
depressant use was associated with a lower risk of MI (model
2; OR, 0.57; 95 % CI, 0.32–0.99), which remained similar
when additionally adjusted for potential intermediate factors
(model 3), as well as when the period of past use was started
later during follow-up (results not shown).
SSRIs, TCAs, and risk of MI
Compared with never use of SSRIs, current use of SSRIs was
associated with a lower risk of MI, although marginally not
statistically significant (OR, 0.65; 95 % CI, 0.41–1.02)
(Table 3). Past use of SSRIs was associated with a higher risk
of MI (OR, 1.42; 95 % CI, 1.06–1.49) compared with never
use of SSRIs. A similar point estimate of current SSRI use was
observedwhen comparedwith past use of SSRIs, although not
statistically significant (OR, 0.58; 95 % CI, 0.23–1.49). These
results did not materially differ after additional statistical ad-
justment for potential intermediate factors (results not shown).
Compared with never use, as well as with past use of
TCAs, current use of TCAs was not associated with a lower
risk orMI (Table 3), although the point estimate of current use
compared with past use was lower.
Additional analyses
Participants who used multiple cardiovascular drugs had a
higher risk of MI (Fig. 1). Furthermore, they used antidepres-
sants more frequently than participants who used no cardio-
vascular drug at the index date. After exclusion of participants
using multiple cardiovascular drugs at the index date, results
for the association between current use of antidepressants and
MI remained similar (OR, 0.63; 95 % CI, 0.38–1.06) after
adjustment for confounding factors.
Eur J Clin Pharmacol (2016) 72:211–218 213
Current use of antidepressants was associated with a higher
risk of all-cause mortality than nonusers of antidepressants
(OR, 1.22; 95 % CI, 1.08–1.38). This was also observed in
current users of SSRIs (OR, 1.32; 95 % CI, 1.10–1.58). How-
ever, no difference in risk of all-cause mortality was observed
between current and past use of any antidepressants, and
SSRIs specifically (SSRIs: OR, 0.95; 95 % CI, 0.80–1.12).
Furthermore, current and past use of TCAs was not associated
with the risk of all-cause mortality.
Discussion
Within the present case-control study, nested in the prospec-
tive Rotterdam Study cohort, current use of antidepressants
was associated with a lower risk of MI. Of the different anti-
depressant drug groups, SSRI use was associated with the
lowest risk of MI, although marginally not statistically signif-
icant and the number of cases using SSRIs was low.
These findings were supported by some of our extra
analyses. First, past use of SSRIs was associated with a
nonsignificantly higher risk of MI which suggests that in
people with the same indication, discontinuation of SSRIs is
followed by disappearance of a protective effect. Because cur-
rent use of antidepressants was not associated with an in-
creased risk of all-cause mortality (e.g., the increased risk of
all-cause mortality was not observed in the comparison be-
tween current and past use of antidepressants), the association
was not explained by confounding due to competing risk.
Second, results remained similar when current use of antide-
pressants was compared with past use of antidepressants. Past
users of antidepressants were assumed to be more comparable
with current users of antidepressants with respect to confound-
ing factors than never users. However, the population of past
users was considerably smaller than the group of never users.
And third, results remained similar after exclusion of partici-
pants with multiple concomitantly dispensed cardiovascular
drugs, indicative of the participants with the highest cardio-
vascular risk.
Our findings are also supported by a number of other
epidemiological studies. Our observation was similar to a
previously published case-control study on the risk of MI
Table 1 Baseline characteristics
of the study population Baseline characteristics
of future MI cases
(N = 744)
Baseline characteristics
of the total cohort
(N = 9499)
Age in years (mean (SD)) 69.7 (8.1) 69.4 (8.7)
Female (N (%)) 333 (44.8) 5787 (60.9)
Body mass index in kg/m2 (mean (SD)) 26.8 (3.4) 26.7 (3.8)
Current smoking (N (%)) 194 (26.1) 1908 (20.1)
Education (N (%))
Basic 145 (19.5) 1,870 (19.7)
Low 295 (39.5) 4,156 (43,8)
Medium 215 (28.9) 2,465 (26.0)
High 90 (12.1) 1,008 (10.6)
Systolic blood pressure in mmHg (mean (SD)) 146 (21) 132 (21)
Diastolic blood pressure in mmHg (mean (SD)) 77 (11) 77 (11)
Total cholesterol in mmol/L (mean (SD)) 6.7 (1.2) 6.4 (1.2)
HDL cholesterol in mmol/L (mean (SD)) 1.2 (0.3) 1.4 (0.4)
History of venous thromboembolism (N (%)) 2 (0.3) 13 (0.1)
History of heart failure (N (%)) 22 (3.0) 239 (2.5)
Depression (N (%)) 4 (0.5) 86 (1.0)
Anxiety (N (%)) 2 (0.3) 53 (0.6)
Glucose-lowering agents (N (%)) 73 (9.8) 476 (5.0)
Antithrombotic agents (N (%)) 86 (11.6) 1035 (10.9)
Blood-pressure-lowering agents (N (%)) 172 (23.1) 2098 (22.1)
Beta-blockers (N (%)) 142 (19.1) 1246 (13.1)
Lipid-lowering agents (N (%)) 40 (5.4) 524 (5.5)
Antipsychotics (N (%)) 5 (0.7) 87 (0.9)
Anxiolytics (N (%)) 31 (4.2) 453 (4.8)
Hypnotics (N (%)) 47 (6.3) 540 (5.7)
Abbreviations: N number of participants, SD standard deviation, HDL high-density lipoprotein
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in users of SSRIs [5]. Furthermore, a lower risk of MI was
observed in users of antidepressants with a high affinity to
the serotonin reuptake transporter, and thus may indicate a
specific effect of serotonin inhibition [6]. However, none
of the other published studies reported a lower risk of MI in
users of SSRIs [7–9] or even observed a higher risk [11,
12]. Differences in study design and availability of infor-
mation on covariates (specifically depression [13–18])
might explain these contradictory results published in the
literature on this topic. Furthermore, to the best of our
knowledge, no studies have yet been conducted investigat-
ing whether the risk of antidepressant-associated bleedings
is different between men and women. In previous studies,
it has been shown that women have a better response to
SSRIs than men [27, 28]; the risk of MI might therefore
also be different between men and women. However, in the
present study, we had a too low number of cases to study
this hypothesis.
In our study population, we did not observe a decreased
risk of MI in users of TCAs. Previous studies showed that the
use of TCAs was associated with an increased risk of MI [6,
10, 11]. However, when compared with past use of TCAs, a
lower risk of MI was observed during TCA use, although not
statistically significant due to the low number of cases that
used a TCA.
Besides data from some of the conducted epidemiological
studies, also data on the relation between serotonin and MI
support our findings. The serotonin receptor 2A (5-HT2A) and
the serotonin transporter are both expressed at the surface of
blood platelets and facilitate the activation and aggregation of
blood platelets as well as coronary vasoconstriction [29, 30].
In patients with depression it has been shown that sensitivity
of the 5-HT2A receptor is increased and expression of the
serotonin transporter decreased [4]. This was thought to be
one of the explanations why patients with depression are at a
greater risk of MI [4]. Also, a high serotonin concentration in
serum was associated with a higher risk of MI [31]. Further-
more, use of SSRIs was associated with a decreased serotonin
and platelet concentration in whole blood and with a lower
platelet activation [32, 33].
For case-control and cohort studies, results might be sub-
ject to residual confounding. To our knowledge, only one
randomized clinical trial investigating the association between
sertraline and risk of MI has been conducted as a secondary
study outcome.Within that study, a 30% lower risk ofMI was
observed in the sertraline-treated patients after a 24-week
treatment period compared with patients on placebo treatment
[9]. However, this difference was not statistically significant,
probably because of the low number ofMI cases. Both groups
had a similar relief in depressive symptoms. Thus, a difference
Table 2 Association between antidepressant use and myocardial infarction
Percentagea Events Model 1b OR (95 % CI) Model 2c OR (95 % CI) Model 3d OR (95 % CI)
Analysis 1Ae
Never use 84.9 553 1 (reference) 1 (reference) 1 (reference)
Current antidepressant use 3.7 17 0.82 (0.59–1.14) 0.76 (0.54–1.07) 0.76 (0.54–1.07)
Past antidepressant use 11.4 80 1.14 (0.91–1.42) 1.12 (0.90–1.40) 1.12 (0.89–1.40)
Analysis 1Bf
Never use 85.0 632 1 (reference) 1 (reference) 1 (reference)
Current antidepressant use 3.8 19 0.77 (0.56–1.06) 0.71 (0.51–0.98) 0.71 (0.51–0.98)
Past antidepressant use 11.2 93 1.18 (0.95–1.46) 1.17 (0.95–1.45) 1.17 (0.94–1.44)
Analysis 2g
Past use 11.2 93 1 (reference) 1 (reference) 1 (reference)
Current antidepressant use 3.8 19 0.72 (0.42–1.23) 0.57 (0.32–0.99) 0.56 (0.32–0.99)
Abbreviations: 95 % CI 95 % confidence interval, OR odds ratio
a As we studied the associations with time-varying exposure analysis, controls contributed more than once in the computations before they were censored
or became a case. For this reason, exposure is reported as a percentage
bMatched on age and sex, further unadjusted
cMatched on age and sex, and adjusted for: history of deep venous thrombosis, history of heart failure, systolic and diastolic blood pressure, highest
obtained level of education, total cholesterol, high-density lipoprotein cholesterol, smoking, blood-pressure-lowering agents, antithrombotic agents,
antipsychotic agents, anxiolytics, hypnotics, depression and anxiety
dModel 2 and additionally adjusted for the potential intermediate factors: body mass index, HDL cholesterol, total cholesterol, statins and diabetes
mellitus
e Analyses with never use of antidepressants as reference, using unimputed data
f Analyses with never use of antidepressants as reference, using imputed data
g Analyses with past use of antidepressants as reference, using imputed data
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in depression during follow-up did not explain the lower risk
of MI in the sertraline-treated patients [13–18]. Together with
the results of our study, these are additional arguments in favor
of a protective effect of antidepressants, in particular SSRIs,
on the risk of MI.
Antidepressants, and specifically SSRIs, have been associ-
ated with an increased BMI [23], elevated serum low density
lipoprotein cholesterol levels [24, 25], and a higher risk of
diabetes mellitus [26], which have all been associated with a
higher MI risk. However, although additional adjustment for
these factors did not materially change the observed associa-
tions, it is unlikely that antidepressants decrease the risk of MI
more than statins do in the first-line prevention of cardiovas-
cular diseases [34]. In addition, it is worth noting that the use
of antidepressants, and especially the SSRIs, has also been
associated with an increased risk of bleeding, presumably
through the effects of antidepressants on blood platelets [35].
This study has strengths and limitations. First, the available
pharmacy dispensing records allowed us to study drug use at
the date of MI. We were able to study antidepressant drug use
in a time-dependent manner and are able to clearly define
episodes during which participants filled antidepressant drug
prescriptions. Second, MI adjudication was done using stan-
dardized definitions using hospital discharge letters and re-
cords of the general practitioner [22]. Next, our study was
limited by the small number of participants with an MI who
were current users of antidepressants, which also limits the
possibility to study the effect of induction and duration. More-
over, we could not ascertain whether the participants were
actually taking the drugs or only picked up their dispensing
without initiation of treatment. Furthermore, we had no
Table 3 Association between
individual antidepressant drug
classes and incident myocardial
infarction
Use of SSRIs Use of TCAs
Percentagea Events OR (95 % CI) Percentagea Events OR (95 % CI)
Analysis 1Ab
Nonuse 92.2 595 1 (reference) 90.6 587 1 (reference)
Current use 1.8 7 0.70 (0.42–1.17) 1.6 9 0.84 (0.53–1.33)
Past use 6.0 48 1.33 (0.97–1.83) 7.8 54 1.05 (0.79–1.41)
Analysis 1Bc
Nonuse 92.4 681 1 (reference) 90.7 672 1 (reference)
Current use 1.8 8 0.65 (0.41–1.02) 1.6 10 0.80 (0.52–1.24)
Past use 5.8 55 1.42 (1.06–1.90) 7.7 62 1.04 (0.79–1.38)
Analysis 2d
Past use 5.8 50 1 (reference) 7.7 54 1 (reference)
Current use 1.8 7 0.58 (0.23–1.49) 1.6 10 0.60 (0.26–1.41)
Matched on age and sex and adjusted for: history of deep venous thrombosis, history of heart failure, systolic and
diastolic blood pressure, maximum level of education, total cholesterol, smoking, blood-pressure-lowering
agents, antithrombotic agents, antipsychotic agents, anxiolytics, hypnotics, depression and anxiety, and current
use of the other antidepressant drug classes (including other antidepressants)
Abbreviations: 95 % CI 95 % confidence interval, OR odds ratio, SSRIs selective serotonin reuptake inhibitors,
TCAs tricyclic antidepressants
a As we studied the associations with time-varying exposure analysis, controls contributed more than once in the
computation of the odds ratios before they were censored of became a case. For this reason, exposure is reported
as a percentage
bAnalyses with never use of antidepressants as reference, using unimputed data
c Analyses with never use of antidepressants as reference, using imputed data
d Analyses with past use of antidepressants as reference, using imputed data. For the analysis on SSRIs, 1 case
currently using had nomatched controls and 5 cases whowere past user had nomatched controls. For the analysis
on TCAs, 8 past users could not be matched. These were therefore not included in the analyses
Fig. 1 Association between concomitantly used cardiovascular drugs
and incident myocardial infarction and the use of antidepressants.
Abbreviations: CI confidence interval, MI myocardial infarction, OR
odds ratio. Analyses adjusted for age, sex, and body mass index
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information available about the reason for stopping antide-
pressant treatment. However, restricting the period of past
use did not change the results. Also, due to the observational
nature of the data, the results may be subject to residual
confounding.
In conclusion, current use of antidepressants was associat-
ed with a lower risk of incident MI. Of the antidepressant drug
groups, use of SSRIs showed the lowest risk of MI. However,
more studies are required to confirm our results.
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